One line pitch

Preventing blindness by empowering eye doctors with an AI assistant for retinal therapy

Scientific one-liner

deepeye empowers ophthalmologists with AI to streamline intravitreal injection processes, driving outcomes & adherence and thus prevent blindness

Short

100+ million people globally are suffering from chronic, vision-threatening retinal diseases, accounting for ⅔ of blindness in the EU & US. Although 20+ million highly effective anti-VEGF therapies ($13 bn) are performed annually, millions of patients are losing vision permanently due to undertreatment or non-adherence to treatment.
deepeye built a precision medicine platform to support ophthalmologists in tailoring treatments for patients, streamlining the therapy process for providers, patients & caregivers and driving outcomes and adherence.
Our bold vision is to prevent 1 million people from blindness by 2030.

Shorter (200 chars)

Despite effective therapy for top causes of vision loss, most patients drop out due to high burden and go blind. deepeye’s AI empowers eye doctors to personalize treatment, get better vision outcomes, and drive therapy adherence.deepeye built a precision medicine platform to support ophthalmologists in tailoring treatments for patients, streamlining the therapy process for providers, patients & caregivers and driving outcomes and adherence.

2 sentences

Despite effective treatment for top causes of vision loss, most patients drop out due to suboptimal results at therapy high burden. deepeye AI-mpowers eye doctors to personalize treatment and (hopefully) prevent millions from retinal blindness.

About deepeye Medical

Millions of patients with vision loss abandon treatment despite effective therapies, leading to blindness. deepeye’s AI technology helps eye doctors tailor eye injections, potentially preventing ⅔ of blindness cases. Based in Munich, deepeye spun out from a leading tele-ophthalmic network, where expert 2nd opinions improved outcomes 3x and halved treatment dropout rates. Collaborating with top pharma and diagnostic firms and drawing insights from a vast dataset spanning hundreds of eye practices globally, deepeye introduces the world's 1st planning support tool for retinal therapies.

Long

100 million people globally suffer from vision-threatening retinal diseases. A $13bn drug can stop patients from vision loss. Still, ⅔ of cases of blindness in EU+US are due to these diseases like wet AMD. We provide an AI-based precision health platform that improves therapy outcomes by up to 6x by boosting:
-Adherence & persistence from 38% to 78% (2x)
-Real-world vision outcomes from 36% to 100% (3x)Our vision is to prevent 1 million additional people from blindness by 2030 by empowering ophthalmologists with AI-based optimal therapy prognosis. Our pre-clinical AI is used by pharma (Novartis, Bayer, Roche), payors, and providers’ associations to gain new insights into their therapy data.Our clinical product currently awaits regulatory approval to provide therapy decision support with 1 click at the point of care. Partnerships with the leading retinal diagnostics companies enable us access to more than >80% of ophthalmic practices globally. Together, we will put our AI in the hands of more than 50k retina specialists and long-term 220k eye doctors worldwide, starting with the EU, US and JP.

Team

100'000+ retinal therapies + 250+ medical device studies / approvals + >204 years working in medical devices or AI (16.2 on average) + 11.7 FTE + 10 nationalities = 1 team to scale the proven clinical benefits of expert 2nd opinion to ophthalmologists worldwide

deepeye Logo

Team pictures

Follow our latest news here

Discover research & studies related to our activity here

Please feel free to contact us if you need any more informations :
Charles Brioix
+33 (0)6 18 57 72 95
pr@deepeye-medical.com